Full year 2025 financial guidance excludes any potential share repurchase or additional M&A activity. CEO Dr. Steve Cutler commented, "ICON continues to navigate dynamic clinical development ...

ICON (NASDAQ:ICLR) stock fell 8% early Tuesday after it issued financial guidance for 2025. The clinical research organization said that it expects to report 2025 revenue of $8.05B to $8.650B ...

ICON plc, (NASDAQ: ICLR), a world-leading clinical research organization powered by healthcare intelligence, today announced its financial guidance for the year ending December 31, 2025.

K92 Mining Inc. (“ K92 ” or the “ Company ”) (TSX: KNT; OTCQB: KNTNF) is pleased to provide its operational outlook for 2025, ...

Tuesday, TD Cowen reaffirmed its Buy rating and $285.00 price target on ICON plc shares (NASDAQ:ICLR), following the company's financial guidance. According to InvestingPro analysis, ICON ...

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR), a world-leading clinical research organization powered by healthcare intelligence, today announced its financial guidance for the year ending ...

The feature is gradually rolling out across the region, with full accessibility already available in key markets including UAE, Saudi Arabia, Egypt, Morocco, and Iraq ...

The revised target comes in response to ICON's 2025 guidance, which Windley noted as being softer than expected. According to InvestingPro data, ICON's stock has experienced a significant 8.71% ...

So far this MLB offseason, the reigning champion Dodgers have signed as many free agents as the rest of their division ...

Richard Francis, Teva Pharmaceuticals CEO, joins 'Money Movers' to discuss the company's quarterly earnings results, drug ...

In 2013, the FDA issued premarket guidance for developers of pulse oximeters in which it recommended that they have “a range of skin pigmentation” represented in their clinical testing of the ...